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Abstract. The effects of fish oil supplementation in Wistar rats are focused on cardiovascular, endocrine, 
metabolic and antioxidant status changes. We determined plasma and liver phospholipid fatty acids (FAs) 
status and plasma lipid concentrations in aged Wistar rats. Our results showed differences in plasma and 
liver FAs profiles as well as plasma chlolesterol (CHOL), triglicerides (TG), high density lipoproteins 
(HDL), low density lipoproteins (LDL), CHOL/HDL ratio (risk factor for atherosclerosis) and LDL/HDL 
ratio (risk for cardiovascular diseases) between treated and control group of animals. In fish oil treated 
group there were statistically significant changes in FAs profile in increasing linoleic acid (LA), dihomo-γ 
linoleic acid, eicopentanoic acid (EPA) and docosapentaenoic acid (DPA) and decreasing in arachidonic 
acid (AA) concentration. Also, liver phospholipids FAs results showed increasing concentrations of vas-
cenic acid, LA, EPA, and DPA and decreasing concentration of AA after supplementation of fish oil com-
pared to control group. However, concentrations of CHOL, LDL and non HDL concentrations decreased 
while HDL increased in fish oil group. CHOL/HDL, LDL/HDL ratios decreased. These findings suggest 
that long term treatment of fish oil in aged Wistar rats can be beneficial in decreasing LDL, and decreas-
ing risk factors for developing atherosclerosis and cardiovascular diseases. (doi: 10.5562/cca1751) 
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INTRODUCTION 
The phospholipid class, FAs composition and cholester-
ol content in biomembranes are basic determinants of 
the physical properties of membranes. They have been 
shown to influence a wide variety of membrane-
dependent functions such as membrane transport, en-
zyme activity and receptor function.1 Biological mem-
branes are organized assemblies of lipids and proteins 
with small amount of carbohydrate. Membrane proteins 
carry out the dinamic processes associated with mem-
brane.2 In higher plants and animals the predominant 
FAs residues are those of the C16 and C18 species pal-
mitic, linoleic and stearic acids. Over one half of the 
FAs residues are unsaturated and are often polyunsatu-
rated.3 Plasma lipoproteins are clasified into five catego-
ries: chylomicrons (transport exogenous TG and CHOL 
from the intestine to the tissues), VLDL, IDL, LDL 
(transport endogenous TG and CHOL from the liver to 
the tissues) and HDL (transport endogenous CHOL 
from the tissus to the liver).4 
Changes in phospholipid structure contents is a 
major marker of atherosclerotic changes.5 Greater intake 
of the long-chain n–3 FAs, EPA and docosahexaenoic 
acid (DHA) has been recommended by a variety of 
scientific and regulatory bodies to reduce population 
risk for coronary artery disease (CAD).6 
The FAs profile of the serum phospholipid is re-
lated to the average dietary FAs intake during the last 3 
to 6 weeks, while the composition of erythrocyte phos-
pholipids depends on the dietary fat intake during the 
preceding months.7 The FAs profile in tissues partly 
reflects not only the dietary fat intake, but also the effi-
ciency of FAs metabolism in the body.8 
Although mammals are able to synthesize satu-
rated FAs from nonfat precursors and unsaturated fatty 
acids of the n–9 and n–7 series, they lack the ∆12 and 
∆15 desaturase enzymes (found in most plants) for in-
sertion of a double bond at the n–6 or n–3 position. 
Thus mammalian cells can not synthesize n–6 or n–3 
polyunsaturated FAs (PUFAs) de novo. The commonly 
consumed PUFAs are linoleic acid (LA) (18:2, n–6) and  
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α-linolenic acid (ALA) (18:3, n–3). Once consumed 
these FAs can be converted to longer chain, more un-
saturated derivatives.9 LA is converted via γ-linolenic 
(18:3, n–6) and dihomo-γ-linolenic (20:3, n–6) acids to 
arachidonic acid (AA; 20:4, n–6). ALA is converted to 
EPA (20:5, n–3) and DPA (22:5, n–3). EPA and DHA 
are termed long chain n–3 PUFAs. These FAs are found 
in oily fish and the preparations known as fish oil.9 
They are involved in regulation of lipid metabolism and 
processes involved in lipid transport and targeting to 
tissues.9 They are components of membranes of all 
cells, contributing to the fluidity of the membrane and 
this is believed to play a role in regulation of activity of 
membrane proteins. Also PUFAs are substrates for the 
synthesis of bioactive molecules such as prostaglandins 
(PG), thromboxanes (TX) and leukotrienes (LT).10 
Eicosanoids formed from the n–3 FA are much less 
potent in causing biological responses, including stimu-
lation of cytokine production and inflammatory reac-
tions than those formed from the n–6 series.10 The im-
mune and inflammatory cells contain many transcription 
factors including NF kappa B (NFκB) which regulates 
the synthesis of cytokines interleukin 1 (IL-1), interleu-
kin 2 (IL2), interleukin 6 (IL-6), tumor necrosis factor- 
α (TNF-α) and interferon-β. EPA reduces the production 
of pro-inflammatory IL-1 and IL-6 as well as TNF-α 
and -β in response to an inflammatory stimulus.10  
When fish oil is provided EPA is incorporated into 
cell membrane phospholipids, partly at the expense of 
AA.9 There is less AA available for eicosanoid synthe-
sis. EPA inhibits the oxidation of AA by cyclooxyge-
nase (COX). Fish oil decreases production of prostag-
landin (PG) like PGE2, of thromboxane (TX) like 
TXA2 and leukotrienes (LT) like LTB4. 
PUFAs can potentially reduce platelet aggrega-
tion, blood clotting, smooth muscle contraction, and 
leukocyte chemotaxis, and can modulate inflamatory 
cytokine production and immune function.9 
Fish oils which are rich in n–3 PUFAs have been 
postulated to be beneficial in several disease states in-
cluding atherosclerosis, hypertension and arthritis.11,12 
The major n–3 FAs found in fish oil are EPA [20:5 
(n–3)] and DHA (22:6, n–3). Fish oils have been shown 
to reduce hepatic lipogenesis and VLDL secretion and 
increase post-heparin plasma LPL activity.13 Fish oil 
rich in EPA and DHA inhibits production of PGE2, as 
well as lymphocyte proliferation and production of 
interferon-γ (IFN-γ).10 Immune function could be im-
proved by PUFAs and among them an n–3 FAs from 
fish oil EPA possess the most potent immunomodulato-
ry activities.10 
An increasing number of clinical studies indicate 
that the consumption of ALA has beneficial effects on 
human health, particularly on cardiovascular diseases 
(CVD). ALA consumption is protective against cardiac 
death and nonfatal myocardial infarction (MI) in pros-
pective and intervention trials.14 The proportion of satu-
rated (SA), monounsaturated (MUFAs), and PUFAs fat 
content may have an effect not only on the ALA con-
version into EPA and DHA, but also on the concentra-
tions of inflammatory markers and on the plasma lipid 
profile.15,16 
Liver has important role in synthesis and metabol-
ism of phospholipids. Liver phospholipids build struc-
ture of hepatocyte membrane, takes part in metabolic 
activities and repairing after metabolic disturbances. 
Some of them lipoproteins are in circulation and a part 
are excreted in bile. Phospholipids of hepatocytes and 
plasma has more percentage of stearic and AA.17  
A large body of evidence shows that hepatic lipo-
genesis is regulated by both nutritional and hormonal 
factors. In particular, it is well documented that dietary 
PUFAs are noticeably effective in inhibiting hepatic 
lipogenesis and in lowering hypertriglyceridemia, n–3 
FAs being more potent than n–6 lipids in this respect.17 
The n–3 PUFAs also decrease production of AA derived 
eicosanoids. Due to lack of Δ6 desaturase, content of 
AA in inflammatory cells depend on the uptake of AA 
synthesized in the liver from plasma it depends on he-
patic desaturases.10  
Furthermore, dietary PUFAs coordinately de-
crease the expression of hepatic genes encoding glyco-
lytic and lipogenic regulatory enzymes involved in the 
flux of glucose to FAs.18 The n–3 PUFAs also play a 
crucial role as ''fuel partitioners'', in that they direct FAs 
away from triacylglycerol storage and toward oxida-
tion.19 They act by upregulating the expression of genes 
encoding proteins involved in FAs oxidation while 
down regulating genes encoding proteins of lipid syn-
thesis.20 On the other hand, MUFAs oleate (C18:1, n–9) 
or SFA like palmitate (C16:0) and medium-chain FAs 
[as present in coconut oil (CO)] do not inhibit either the 
activities or the expression of the lipogenic enzymes.21 
Palmitat (16:0) the normal product of FAs synthe-
sis pathway is the precursor of longer-chain saturated 
and unsaturated FAs through the actions of elongases 
and desaturases. Elongases are present in both the mito-
chondrion and the endoplasmatic reticulum but the 
mechanisams of elongation at the two sides differ. The 
difference is in final reduction terminal redox coen-
zyme.22 Unsaturated FAs are produced by terminal 
desaturases. Mamals systems contain four terminal 
desaturases of broad chain-lenth specificities designated 
∆9, ∆6, ∆5, and ∆4 fatty acyl-CoA desaturases. Mam-
malian terminal desaturases are components of cytoch-
rome b5 and NADH-cytochrome b5 reductase. A varie-
ty of unsaturated FAs may be synthesized by combi-
nations of elongation and desaturation.22 
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EXPERIMENTAL 
Materials and Methods 
The experiments were carried out on adult male Wistar 
rats (280 g) housed in stainless steel cages with wired 
floors and with free access to food (Veterinarski zavod, 
Subotica) and water, in a room under controlled condi-
tions (12 h light/dark cycles, temperature 22±2 °C). Rats 
were randomly assigned to experimental or a control 
group. All experiments were done according to our 
Institutional guidelines for animal research and princip-
als of the European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other 
(Official Daily N. L 358/1-358/6, 18, December 1986). 
Wistar rats were divided into two groups of ten 
animals: control and treated group (fish oil, 45 mg EPA 
and 30 mg DHA per day, Natura Wealth, Nordvik). The 
model of rat n–3 feeding was the modification of animal 
feeding protocol described by Tepsic et al.23 Individual-
ly caged, body weight and age-matched rats were 
treated as follow: control (n = 10) and n–3 enriched diet 
(n = 10) for 6 weeks. Each morning rats were indivi-
dually caged and fed only by one briquette saturated 
with the exact amount (200 µL) of saline (control rats) 
or 200 µL fish oil, (45 mg EPA and 30 mg DHA per 
day) (Natura Wealth, Nordvik). The same amount of 
food was return to rat cages 30–40 min after individual 
feeding treatment. The body weight was measured every 
day and animals were sacrificed in the morning after 12 
h of fasting. 
Blood samples (6–8 cm3) from all rats were ob-
tained via aorta abdominalis puncture and collected in 
tubes containing sodium citrate (3.8 % w/v) as anticoa-
gulant. Immediately after sacrificing, part of the liver 
was frozen at –80°C. 
 
Plasma Biochemical Parameters 
Cholesterol and triglyceride concentrations were meas-
ured in plasma using the automated enzymatic methods 
with cholesterol oxidase, and glycerol oxidase, respec-
tively (EliTech Diagnostic, Sees, France). Serum high-
density lipoprotein (HDL) cholesterol was measured 
after other classes of lipoproteins had been precipitated 
with phosphotungstic acid and magnesium chloride 
(Lopes-Virela et al. 1977).24 LDL cholesterol was  
estimated using Friedewald formula (Friedewald et 
al.1972).25 
 
Total Lipid Extraction 
The method consists of homogenizing the tissue with a 
2:1 chloroform/methanol mixture and washing with 5 
times smaller volume of water or NaCl (0.9 g in 100 mL 
of water). The resulting mixture separates into two 
phases. The lower phase is the total pure lipid extract. In 
details, liver tissue (1 g) was lyophilized and chloro-
form/methanol (2:1) and butylhydroxytoluene (BHT) as 
antioxidant were mixed. When the mixture is allowed to 
stand a biphasic system was obtained. After evacuation 
water was added. After centrifugation upper phase were 
put away until complete separation of the system. Fur-
ther evacuation was done with 2:1 solvent systems: 
methanol/benzene, acetone/benzene, and ethanol/ 
benzene. Adding of chlorophorm and its evacuation and 
after it adding hexane in sample made it ready for thin 
liquid chromatography (TLC) (23). 
 
FAs Analysis 
The phospholipid fraction was isolated from the ex-
tracted lipids by one-dimensional (TLC) neutral lipid 
solvent system of hexane:diethyl ether:acetic acid 
(87:2:1) using Silica Gel GF plates (C. Merck, 
Darmstadt, Germany). The phospholipid fraction was 
scraped into glass tubes and phospholipid FAs methyl 
esters were prepared by transmethylation with sodium 
hydroxide (2 mol dm–3) in methanol (heated at 85 °C for 
1 h) and after that sulfuric acid (1 mol dm–3) in metha-
nol (heated 85 °C for 2 h). After 30 minutes, samples of 
esters were centrifuged, upper phase were put into tubes 
and evaporated with tehnical nitrogen. FAs methyl  
esters derivatives formed from isolated plasma phospho-
lipids fraction were separated by Gas Chromatography 
(GC) using Shimadzu GC 2014 equipped with a flame 
ionization detector and DB-23 fused silica gel capillary 
column. The flame ionization detector was set at 250 
°C, the injection port at 220 °C, and the oven tempera-
ture programmed from 130 to 190 °C at the heating rate 
of 3 °C/min.26 
Comparing sample peak retention times with au-
thentic standards (Sigma Chemical Company) and/or 
the (PUFA)-2 standard mixtures (Restec) identified 
individual FAs methyl esters.  
 
Estimated Activities of Desaturase System 
Several fatty-acid indexes, reflecting desaturase and 
elongase activity, were derived from the primary data.27 
The ratios of 20:4/20:3, 20:3/18:2 and 22:6/22:5  
were used as a measure of estimated ∆5-desaturase, ∆6-
desaturase and ∆4-desaturase activities respectively, 
while 18:1/18:0 and 18:0/16:0 ratios represented esti-
mated ∆9-desaturase and elongase activities. 
 
Statistical Analysis 
All the results are expressed as the mean±SD. Normali-
ty was tested using the Kolmogorov–Smirnov test be-
fore statistical analysis. One-way ANOVA and the Stu-
dent t-test were used to compare the normally distri-
buted variables. Where ANOVA revealed a significant 
effect, Tukey post hoc test was administered to identify 
differences between the groups. The differences were 
considered significant at p ≤ 0.05.  
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RESULTS 
The results of our study showed lipid metabolism status 
in aged rats and also changing in lipid parameters after 
treatment with fish oil in six weeks treatment. 
Our results of biochemical measurements showed 
changes in concentrations of CHOL, HDL, LDL, non-
HDL and its ratios showing cardiovascular and atheros-
clerosis risk (Table 1). 
CHOL concentration, LDL concentration and non 
HDL concentrations significantly decreased in treated 
group at the end when compared to treated group at start 
and also vs. control group. Concentration of LDL frac-
tion significantly decreased in treated group at the end 
as compared to treated group at start and also vs. control 
group. Concentration of TG was slightly decreased at 
the end when compared to start of the study as well as 
vs. control group, although the changes were not sta-
tistically significant (Table1). The ratios between 
CHOL and HDL, (as a factor of cardiovascular risk28), 
were significantly lower in treated group at the end than 
in the same group at start and also than in control group. 
Furthermore, LDL/HDL ratios (as a factor of atheroscle-
rosis risk28), were significantly decreased after treatment 
when compared to baseline values and to control group 
as well (Table 2). 
Concentrations of plasma and liver phospholipids 
profiles were also changed after supplementation with 
fish oil capsules in six weeks treatment. Our results 
showed statistically significant increasing in plasma 
phospholipids concentrations of LA, dihomo-γ linolenic 
acid, EPA and DPA and decreasing in AA concentration 
after supplementation with fish oil (Table 3). 
Plasma phospholipids concentrations of SFA, 
MUFA, PUFA, n–3, n–6 showed no statistically signifi-
cant changes (Table 3), while liver phospholipids con-
centrations of SFA, MUFA, PUFA, n–3 increased and  
n–6 and n–6/n–3 ratio decreased after supplementation 
of fish oil when compared to control group (Table 4). In 
addition, liver phospholipids FAs results demonstrated 
significantly increased concentrations of vascenic acid, 
LA, EPA, and DPA and significantly reduced concen-
tration of AA after supplementation with fish oil, than in 
control group (Table 4). 
Treatment with fish oil also induced changes in  
estimated activity of desaturase and elongase system in 
both plasma and liver phosholipids. The estimated  
activities of Δ4, Δ5, Δ6 desaturase in plasma decreased 
after the teatment, while the estimated activities of Δ4 
Table 1. Serum biochemical parameters in control and treated group of aged Wistar rats 
 CHOL (mmol/L) HDL(mmol/L) LDL (mmol/L) TG (mmol/L) 
Control group 0.803±0.22 0.171±0.04 0.517±0.19 0.254±0.06 
Omega 3-start 0.74±0.21 0.16±0.04 0.45±0.17 0.31±0.08 
Omega 3-end 0.54±0.14*## 0.23±0.07**# 0.17±0.13***### 0.25±0.06 
* p < 0.05; ** p < 0.01; *** p < 0.001 – when compared before and after treatment. 
# p < 0.05; ## p < 0.01, ### p < 0.001 – when compared to control group, as determined by ANOVA followed by the Tukey post hoc test. 
Table 2. Atherosclerosis and cardiovascular risk factors in control and treated group of aged Wistar rats 
 NON-HDL CHOL/HDL LDL/HDL NON HDL/HDL 
Control group 0.65±0.10 4.89±1.53 2.80±0.85 3.89±1.53 
Omega 3-start 0.60±0.14 5.73±1.96 2.81±0.94 3.39±1.04 
Omega 3-end 0.31±0.13***### 2.31±0.61***## 0.82±0.38***### 1.15±0.48**### 
* p < 0.05; ** p < 0.01; *** p < 0.001 – when compared before and after treatment. 
# p < 0.05; ## p < 0.01, ### p < 0.001 – when compared to control group, as determined by ANOVA followed by the Tukey post hoc test. 
Table 3. Plasma phospholipids fatty acid profile in aged Wistar rats
Fatty acids (%) Before After (Fish oil) 
16:0 28.34±1.89 26.23±3.75 
16:1 0.73±0.50 0.77±0.42 
18:0 24.36±1.46 27.91±2.98 
18:1, n–9 8.23±3.03 6.89±0.91 
18:1, n–7 2.04±0.60 2.90±0.50 
18:2 14.07±1.41 17.23±1.66** 
20:3 0.69±0.13 1.31±0.46* 
20:4 14.77±2.43 8.87±2.21* 
20:5 0.41±0.22 0.72±0.21* 
22:4 0.36±0.19 0.47±0.23 
22:5 0.67±0.17 1.54±0.40** 
22:6  5.34±1.39 5.03±1.19 
SFA 52.70±1.18 54.13±3.97 
MUFA 10.99±3.94 10.56±0.88 
PUFA 36.32±3.65 35.18±4.12 
n–3 6.42±1.46 7.28±1.61 
n–6 29.89±3.02 27.89±3.10 
* p < 0.05; ** p < 0.01 – student test. 
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and Δ5 desaturases were also decreased in liver. The 
estimated activity of elongase in liver was also de-
creased comparing to control group (Tables 5 and 6). 
 
DISCUSSION 
Membrane fluidity depends on alterations in the phos-
pholipid fatty acid composition, e.g. on FAs chain 
length, degree and type of unsaturation. The saturated 
FAs (16:0 and 18:0), as well as the ratio between satu-
rated and unsaturated FAs tend to decrease membrane 
lipid fluidity.29,30 Dietary FAs profile influences tissue 
FAs composition as well as membrane FAs composition 
and membrane protein function.31 Feeding animals diets 
with a high ratio of PUFAs improved insulin action, 
glucose transport and other cellular processes.32 
Our results are in line with the other studies. In a 
study by Calviello et al.33 Wistar rats received by ga-
vage EPA or DHA (360 mg/kg/day), for 1 to 4 weeks. 
EPA treatment increased EPA and DPA content in 
plasma. DHA treatment mainly increased DHA content. 
Both tretment decreased AA content and n–6/n–3 PUFA 
ratio in the membranes, withouht modifying the unsatu-
ration index.33 
Froyland et al.34 clarified the effects of purified es-
ters of EPA and DHA on lipid metabolism in rats.  
The animals were fed by orogastric intubation 1 
g/kg/day for 3 months. That study showed that esters of 
EPA (EPA-EE) and esters of DHA (DHA-EE), lowered 
plasma cholesterol level, whereas only EPA-EE lowered 
the amount of plasma triacylglycerol. In liver micro-
somes EPA-EE raised HMG-CoA reductase and  
acyl-CoA cholesterol acyltransferase activities. An 
inhibition of HMG-CoA reductase activity in DHA-EE 
treated rats maight have contributed to the hypocholes-
terolemic effect.34 
According to Leigh-Firbank et al.35 fish oil can re-
duce TG and cardiovascular risk. Increases in platelet 
EPA and DHA were postively associated with the in-
crease in LDL oxidation. Animal model36 and in vitro 
results37 suggested that EPA rather than DHA may be  
a reducing TG agent. n–3 PUFAs supplementation 
showed an impact on overall LDL concentraton with 5 
to 10 % increase.36 This study indicated that despite an 
increase in LDL oxidation and LDL concentration fol-
lowing fish oil intervention there was an increase in 
LDL density which may have counterected these proa-
therogenic trends. 
Comparing our results on plasma phospholipids 
FAs profile in aged rats (control group) in our study, 
with Wistar rats of 8 weeks of age, there were no sig-
nificant changes38 in SFA, MUFA and PUFA concentra-
tions, as well as in separate FAs percentage. Diet treat-
ment changes in profile of FAs39 depend on type of diet, 
suggesting that amount of fat has a greater influence on 
obesity and FAs profile than the type of fat consumed.34  
Plasma FAs can enter liver when unesterified by 
passive diffusion or facilitated transport40 or via hepato-
cyte lipoprotein receptors when esterified within lipo-
proteins.41 Comparing FAs composition of total liver 
Table 4. Liver phospholipids fatty acid profile in aged Wistar rats 
Fatty acids (%) control group ω-3 group 
16:0 18.15±1.18 25.50±2.39*** 
16:1 0.65±0.32 0.69±0.12 
18:0 26.38±1.88 26.27±3.03 
18:1, n–9 5.38±1.12 4.75±0.49 
18:1, n–7 2.03±0.34 2.95±0.63* 
18:2 14.43±1.37 17.35±1.68** 
18:03 0.05±0.01 0.07±0.01 
20:3 1.68±0.36 1.73±0.54 
20:4 23.02±3.26 10.99±1.42*** 
20:5 0.50±0.09 2.64±0.67*** 
22:4 0.22±0.11 0.53±0.44 
22:5 0.98±0.11 1.52±0.08*** 
22:6 4.90±1.04 5.00±0.24 
SFA 51.77±2.72 44.54±1.033***
MUFA 8.4±0.97 8.05±1.09*** 
PUFA 28.85±1.82 22.76±1.06*** 
n–3 9.23±0.84 6.44±1.10*** 
n–6 30.61±2.64 39.35±3.73*** 
n–6/n–3 3.35±0.51 6.30±1.46*** 
* p < 0.05; ** p < 0.01; *** p < 0.001  – student test. 
Table 5. Estimated liver desaturase and elongase activities in 
control and treated group in aged Wistar rats 
 control group after treatment 
22:6/22:5 (Δ 4 ) 5.07±1.26 3.29±0.25## 
20:4/20:3 (Δ 5)  14.37±4.05 6.72±1.59### 
20:3/18:2 (Δ 6) 0.12±0.03 0.099±0.02 
18:1/18:0 (Δ 9) 0.20±0.03 0.18±0.04 
18:0/16:0 elongase 1.46±0.18 1.04±0.17### 
## p < 0.01; ### p < 0.001  – student test. 
Table 6. Estimated plasma desaturase and elongase before and 
after treatment in aged Wistar rats 
 before treatment after treatment 
22:6/22:5 (Δ4 ) 8.48±3.37 3.32±0.56** 
20:4/20:3 (Δ5)  21.57±4.01 7.48±3.56*** 
20:3/18:2 (Δ6) 0.05±0.01 0.07±0.02* 
18:1/18:0 (Δ9) 0.34±0.14 0.25±0.05 
18:0/16:0 elongase 0.86±0.10 1.09±0.22 
* p < 0.01; ** p < 0.01; *** p < 0.001  – student test. 
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phospholipids of aged Wistar rats in our study, with 8 
weeks old rats from the Ristic-Medic et al.,42 we found 
that overall SFA were significantly increased, MUFA 
and PUFA significantly decreased in our aged Wistar 
rats. Treatment with fish oil capsules in our experiment 
improved overall unsaturation, increasing n–3, but de-
creasing n–6 FAs. When compared our results with 
Wistar rats aged 8 weeks,42 this unsaturation index was 
even lower, suggesting that old rats had better response 
to fish oil therapy. 
Comparing FAs composition of total liver phos-
pholipids of aged Wistar rats in our study with FAs 
composition of total heart phospholipids of 6 to 8 weeks 
old Wistar rats,43 SFA were higher and MUFA and 
PUFA were lower in older rats. Also, oleic acid and LA 
were both significantly lower, while AA was higher in 
liver of aged rats. It seems that aging itself is a risk 
factor and at least in part lead to higher saturation of 
FAs in plasma and tissues phospholipids as well.  
Furthermore, we compared our results of liver FA 
composition with 3 weeks Wistar rats in a study by 
Kawai et al.44 The baseline percentage of total SFA was 
higher in our aged rats, but with after fish oil supple-
mentation, unsaturated index increased more than in 3 
weeks Wistar rats used in that study.44  
Dietary FAs composition is significantly corre-
lated to cell membrane FAs composition. n–3 FAs of 
fish oils are known to be elongated and are desaturated 
to a greated extent than n–6 FAs, producing a higher 
unsaturation index in fish oil-fed rats.45 Carpentier et 
al.46 support the view that the FAs pattern of liver phos-
pholipids and TG can be evaluated from measurment 
made in plasma for the same lipids. The measurment of 
selected long-chain n–3 PUFAs in erythrocytes could 
help to identify those subjects with a relative deficiency 
in those n–3 FAs and to assess the correction of such a 
defect in response to an increase in their dietary in-
take.46 
Many studies have examined the regulation of 
mammals elongases at the level of enzyme activity. 
Also, examinations are focused on nutritional and tis-
sue-specific regulation of elonase expression more re-
cently. Elongases and desaturases work in concert to 
synthesize MUFAs and PUFAs. In rat liver Elovl-5 is 
predominant elongase.47 Rat hepatic Elovl-5 and ∆5 and 
∆6 desaturases are coordinately regulated by diet and 
during postnatal development. The low elongase activi-
ty in fetal livers correlates with the Elovl-1, Elovl-2 and 
Elovl-6 low expression in both fetal and adults liver. 
Elovl-5 is responsible for major FAs elongation and is 
capable of elongating 16:0, 18:0, 20:0, 22:0 and 24:0 
saturated FAs rather then monounsaturated (18:1, n–9) 
and polyunsaturated (20:4, n–6) FAs. 
Rat hepatic Elovl-5 expression is regulated at the 
pretranslational level by dietary n–3 PUFAs and PPARα 
agonist and during postnatal development. Unlike ∆5, 
∆6 and ∆9 desaturases, the elongases do not display 
uniform responce to fish oil or PPARα agonist.48 For 
example; rat heart does not synthesize DHA from  
α-LNA owing to the absence of elongase-2, but must 
obtain its DHA entirely from plasma. 
In this paper we were not measure the activities of 
desaturase and elongase system, but we estimated their 
activities according to ratios of specifics FAs. However, 
we found a significant decrease in estimated activities of 
∆4 and ∆5 in both plasma and liver of treated rats. In 
addition, a slight but significant increase in estimated 
∆6 desaturase activity was shown in liver, while a de-
crease in the estimated activity of elongase was detected 
in plasma of Wistar rats after fish oil supplementation. 
 
CONCLUSION 
The results of our study showed that 6 weeks of fish oil 
treatment of aged Wistar rats significantly improved 
lipid status and risk factors for atherosclerosis and car-
diovascular disease. Also, we found a significant in-
crease in most favorable FAs of n–3 series (EPA, DPA 
etc.), and decrease of saturated as well as n–6 PUFAs, 
particularly AA, in both plasma and liver, indicating 
markedly improved FAs profile of phospholipids in 
supplemented rats. The treatment with fish oil affected 
the estimated activities of desaturase and elongase sys-
tem as well. Considering changes in FAs profile in 
phospholipids during aging, fish oil supplementation 
could have beneficial effects, and our future examina-
tion will address it.  
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